Novarock biotherapeutics

NovaRock Biotherapeutics is a clinical-stage biotechnology company that specializes in the discovery and development of innovative antibody therapies for cancer and autoimmune diseases. Founded in 2018 by veteran scientists, the company focuses on advancing biologics from initial discovery through to commercialization. Their platform utilizes proprietary antibody engineering to create targeted therapeutic solutions, with a pipeline that includes candidates such as NBL-012, NBL-015, NBL-020, and NBL-028, which are designed to address various solid tumors and inflammatory conditions.

By targeting specific markers like Claudin-18.2 and Claudin-6, NovaRock seeks to provide safer and more effective treatment options for patients with significant unmet medical needs. The company actively advances its clinical programs through FDA-cleared investigational new drug (IND) applications and has established strategic partnerships and licensing agreements to expand the development and commercialization of its therapeutic candidates in international markets. These efforts are supported by clinical trials focused on evaluating the safety, pharmacokinetics, and efficacy of their candidates in patients with advanced malignant tumors.